AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31185906
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral paracetamol
Trial: 26194675
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HFRT)
Trial: 26194675
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy (STRT)
Trial: 20708287
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg (slow-release)
Trial: 19213787
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg intravenously)
Trial: 17093248
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg on days 0 and 4)
Trial: 16824149
Drug: Daclizumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (50 mg on days 1 and 14)
Trial: 10831476
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment of bipolar I disorder with anxiety symptoms
Trial: 10831476
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment of bipolar I disorder without anxiety symptoms
Trial: 9118516
Drug: Prostacyclin (epoprostenol)
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (epoprostenol) infusion for 12 weeks in addition to conventional therapy (n = 41)
Trial: 9118516
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy alone for 12 weeks (n = 40)
Trial: 8472628
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GL‐G injection (intramuscularly)
Trial: 8472628
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GL‐G injection (intravenously)
Trial: 8472628
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GL‐G injection
Trial: 3525176
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (ID-MTX) and prednisone (PRED)
Trial: 31936495
Drug: Biophysical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biophysical therapy
Trial: 29570546
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy (MT) sessions
Trial: 24726166
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with optimal medical therapy
Trial: 24726166
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone (MED)
Trial: 18753099
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (n = 60)
Trial: 16293352
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg/day as a single dose)
Trial: 16698134
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg/day)
Trial: 8143832
Drug: Oral indomethacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral indomethacin, 50 mg t.d.s. for 3 days
Trial: 26609122
Drug: Trauma-Focused (TF)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused (TF) treatment (8 sessions prolonged exposure or eye movement desensitization)
Trial: 21911136
Drug: Daclizumab (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (54 patients, group D) plus cyclosporine (CsA), mycophenolate mofetil and steroids
Trial: 21911136
Drug: Thymoglobulin (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (55 patients, group T) plus cyclosporine (CsA), mycophenolate mofetil and steroids
Trial: 16966688
Drug: oblimersen sodium
RxNorm normalized name: oblimersen
DrugBank: Oblimersen (DB13811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oblimersen sodium plus dacarbazine (1,000 mg/m2)
Trial: 14767414
Drug: General program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General program of psychomotor therapy (GPMT)
Trial: 11517472
Drug: Semax (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semax (12 mg for moderate severity, 18 mg for severe strokes, treatment course of 5 to 10 days)
Trial: 8474482
Drug: Levodopa therapy
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa therapy after apomorphine test
Trial: 3779035
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g doses four times a day for 2 days prior to and during the study)
Trial: 3779035
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg single oral dose)
Trial: 28714788
Drug: Deep Oscillation
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Oscillation Therapy (DOT)
Trial: 28054902
Drug: Novel goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel goal-directed hemodynamic optimization therapy (GDHOT) based on major vasopressor and inotropic therapy (SG)
Trial: 28054902
Drug: Standard goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard goal-directed hemodynamic optimization therapy (GDHOT) (CG)
Trial: 24953368
Drug: Tissue-selecting therapy
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-selecting therapy (TST)
Trial: 12960371
Drug: NCX-4016 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX-4016 (800 mg twice a day)
Trial: 12960371
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice a day) with aspirin
Trial: 12960371
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice a day) with NCX-4016
Trial: 12960371
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and NCX-4016
Trial: 8694619
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg methylprednisolone in the pump prime (group II)
Trial: 8694619
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid (group I)
Trial: 1751270
Drug: Extradural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural analgesia with continuous infusion of 0.25% bupivacaine with fentanyl
Trial: 1751270
Drug: Extradural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural analgesia with continuous infusion of 0.25% bupivacaine without fentanyl
Trial: 1751270
Drug: Parenteral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioid analgesia
Trial: 30425008
Drug: Clinical medication
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical medication review (CMR) focused on personal goals using Goal Attainment Scaling (GAS)
Trial: 30425008
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of recommendations for GAS-related drug-related problems (DRPs)
Trial: 29560909
Drug: Accelerated intermittent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated intermittent theta burst stimulation (aiTBS) treatment, 20 iTBS sessions applied to the left dorsolateral prefrontal cortex (5 daily sessions spread over 4 days)
Trial: 27333958
Drug: Aster spathulifolius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aster spathulifolius Maxim extract (700 mg/d of ASE)
Trial: 25234526
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg and Celecoxib 400 mg (experimental group)
Trial: 25234526
Drug: Lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder 2 g (placebo group)
Trial: 19384168
Drug: Standard-dose CsA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CsA
Trial: 19384168
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of CsA
Trial: 19384168
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with serum creatinine ≤ 1.5 mg/mL
Trial: 17587625
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injection plus therapeutic exercise
Trial: 15986724
Drug: Functional Swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Swallowing Therapy (FST)
Trial: 12147313
Drug: 1000 IU/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU/h intravenous unfractionated heparin (UFH), n=70
Trial: 12147313
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral aspirin, n=97
Trial: 12013486
Drug: Low-sodium mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium mineral water (sodium, chloride and bicarbonate < 0.02 mmol/l)
Trial: 12013486
Drug: Sodium bicarbonate-rich
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate-rich mineral water (sodium 39.3 mmol/l, chloride 6.5 mmol/l, bicarbonate 48.8 mmol/l)
Trial: 12013486
Drug: Sodium chloride-rich
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride-rich mineral water (sodium 84.5 mmol/l, chloride 63.7 mmol/l, bicarbonate 21.9 mmol/l)
Trial: 1601536
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum plus psychological treatment (NG-PT)
Trial: 1601536
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum plus psychological treatment and partner support (NG-PT-PS)
Trial: 25528834
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) escitalopram
Trial: 20478877
Drug: Medication switch
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switch alone (alternate SSRI or venlafaxine)
Trial: 20478877
Drug: Medication switch
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switch plus cognitive‐behavioral therapy (CBT)
Trial: 19085343
Drug: Aliskiren/HCT 300/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/HCT 300/12.5 mg
Trial: 19085343
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg monotherapy
Trial: 12881590
Drug: Oral carbenoxolone
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to patients with ocular hypertension.
Trial: 12881590
Drug: Oral carbenoxolone
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to healthy volunteers.
Trial: 10320172
Drug: Intraperitoneal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal lidocaine (0.5% in 80 mL)
Trial: 10320172
Drug: Both IM
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IM morphine (10 mg in 1 mL) and intraperitoneal lidocaine (0.5% in 80 mL)
Trial: 10320172
Drug: IM morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM morphine (10 mg in 1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Trial: 10320172
Drug: IM isotonic
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM isotonic sodium chloride solution (1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Trial: 1888692
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 20 mg of ketanserin
Trial: 1888692
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg of ketanserin
Trial: 28487911
Drug: Ziyinqingre prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziyinqingre prescription (Chinese Traditional Medicine), administered twice a day for two weeks
Trial: 28487911
Drug: Montelukast Sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast Sodium tablets, 10mg once a day for two weeks (Control)
Trial: 24263469
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL Turkish coffee (57 mg caffeine/100 mL)
Trial: 22640678
Drug: Sydney Magnoglide
RxNorm normalized name: Sydney golden wattle pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sydney Magnoglide and comprehensive fixed appliance therapy
Trial: 15764779
Drug: Potassium dichromate
RxNorm normalized name: Potassium dichromate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium dichromate C30 globules, 5 globules administered twice daily at intervals of 12 h
Trial: 12444480
Drug: Association between
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association between size and colour of square blocks (e.g. red = large; yellow = small)
Trial: 24439651
Drug: Chamomile Extract
RxNorm normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile Extract 100 mg three times a day
Trial: 24439651
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (MA) 250 mg three times a day
Trial: 21623000
Drug: DMARD methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD methotrexate, sulphasalazine and hydroxychloroquine in combination (COMBO)
Trial: 9605644
Drug: Granulocyte colony‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) (lenograstim; 5 microg/kg body weight per day subcutaneously)
Trial: 7998486
Drug: Intravenous nimodipine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nimodipine, 2 mg per hour for 7 days
Trial: 1617931
Drug: roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (150 mg b.i.d.)
Trial: 2568348
Drug: D-amphetamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (20 mg)
Trial: 26218228
Drug: Direct treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct treatment (Lidcombe Program)
Trial: 26218228
Drug: Indirect treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect treatment (RESTART-DCM treatment)
Trial: 18801158
Drug: Weekly chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly chloroquine (Control)
Trial: 11052438
Drug: Ketamine, 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine, 0 to 5 mg/kg/h plus fentanyl, 0.1 microg/kg/min
Trial: 3315778
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily for 3 days
Trial: 3315778
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg in a single administration
Trial: 3315778
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg in a single administration
Trial: 26973701
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (310 mg choline bitartrate twice daily for 6 weeks)
Trial: 16353868
Drug: Neoton in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoton in combination with ischemic training
Trial: 16353868
Drug: Standard antianginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antianginal therapy
Trial: 7655128
Drug: ivpb (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivpb (intravenous piggyback) infusion of tobramycin sulfate 2 mg/kg at 100 mL/h for 30 minutes
Trial: 7655128
Drug: slow CRIS
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow CRIS (controlled-release infusion system) using a 20-mL vial at 60 mL/h for 1 hour
Trial: 7655128
Drug: fast CRIS
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fast CRIS using a 20-mL vial at 120 mL/h for 1 hour
Trial: 7565947
Drug: Fialuridine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks
Trial: 2164771
Drug: Allopurinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (50 mg qds)
Trial: 2164771
Drug: DMSO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO (500 mg qds)
Trial: 7028045
Drug: 5.6‐benzo‐alpha‐pyron +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.6‐benzo‐alpha‐pyron + 3',4',7‐tris‐(hydroxy‐ethyl)‐rutin (coumarin + troxerutin, Venalot) at 1 mg/kg/d related to the coumarin content
Trial: 14571187
Drug: Inactivated Mycobacterium
RxNorm normalized name: Mycobacterium phlei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Mycobacterium vaccae (MV) vaccine
Trial: 15634953
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (CV)
Trial: 21594407
Drug: Peoscopy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peoscopy and treatment of male partners, condom use for one year (Group A, n=64)
Trial: 21594407
Drug: No peoscopy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peoscopy, no treatment of male partners, condom use for one year (Group B, n=79)
Trial: 21594407
Drug: Peoscopy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peoscopy and treatment of male partners, no condom use (Group C, n=40)
Trial: 21594407
Drug: No peoscopy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peoscopy, no treatment of male partners, no condom use (Group D, n=63)
Trial: 27529226
Drug: Isoflavonoid‐rich herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavonoid‐rich herbal preparation (500 mg)
Trial: 24619793
Drug: 1.5 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/m2 glutathione
Trial: 20626402
Drug: Ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA)
Trial: 20626402
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg (ROSUVA)
Trial: 20626402
Drug: Ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) in patients with T2DM
Trial: 20626402
Drug: Ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) in patients without T2DM
Trial: 16192765
Drug: AQUAVAN Injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AQUAVAN Injection (AQ) at doses of 5, 10, 15, 20, 25, or 30 mg/kg
Trial: 16192765
Drug: AQUAVAN Injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AQUAVAN Injection (AQ)
Trial: 16192765
Drug: PropofolD (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PropofolD (50 mg/min)
Trial: 16192765
Drug: AQUAVAN Injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AQUAVAN Injection (AQ) and PropofolD
Trial: 10411363
Drug: Zofenopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril (ACE inhibitor) given within 24 hours of symptom onset
Trial: 7586247
Drug: Enoxaparin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (20 mg, 40 mg, 1 mg/kg, 2 mg/kg)
Trial: 25586754
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CBT + Sertraline)
Trial: 21073983
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral codeine
Trial: 11166973
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual comparison group